CoreBone Raises $3.7 Million Investment to Commercialize its Bioactive Bone Graft Material for Dental and Orthopedic Treatments & Expand Activity in China

Rhea-AI Summary

CoreBone, based in Tel Aviv, Israel, has announced a successful investment round, raising $3.7 million. The investment includes $3 million from the Guangzhou Sino-Israel Biotech Investment Fund for its Chinese subsidiary, alongside $700,000 from The Trendlines Group and Agriline. This funding will facilitate the expansion of CoreBone's bioactive, coral-based bone graft materials into the rapidly growing Chinese market, which bans the import of foreign human-derived grafts, thus presenting a unique opportunity for CoreBone's products.

Positive

• Raised $3.7 million to accelerate sales efforts in China.
• Investment from GIBF demonstrates confidence in CoreBone's growth potential.
• Unique coral-based graft material addresses unmet medical needs in China.

Negative

• None.

TEL AVIV, Israel, Oct. 4, 2021 /PRNewswire/ -- CoreBone, a company that produces bioactive, coral-based bone graft material, announced that it has completed an investment round of $3.7 million. The Guangzhou Sino-Israel Biotech Investment Fund ("GIBF"), which focuses on introducing Israeli medical technologies to the Chinese market, invested $3 million in CoreBone's Chinese subsidiary; The Trendlines Group and Agriline (a trust of which Vincent Tchenguiz is a discretionary beneficiary) invested $700,000. The funds will be used for extending CoreBone's commercial global presence, primarily in China, which is the world's fastest growing market.

CoreBone develops and sells bioactive bone graft material for dental and orthopedic indications. It is the only company that uses cultured coral for bone grafting. Corals are grown on Moshav Ein Yahav in the south of Israel, in a closed, controlled aquatic (aquarium) system using proprietary technology and laboratory-made sea water enriched with bioactive nutrients and CoreBone's own coral breeding source. The coral has similar properties to human or animal bones and replaces the need for using animal or human bone for bone grafting. This eliminates the risk of disease transfer associated with these products. In China, the import of foreign human-derived bone grafts is banned – creating a tremendous growth opportunity for CoreBone's products.

Commenting on the investment, CoreBone CEO Ohad Schwartz said, "This investment in CoreBone will accelerate our sales efforts in China. CoreBone's graft material provides all the required bone formation qualities and more, without the limitations associated with animal or human sources. We are excited to bring this alternative technology to the bone graft market worldwide."

Prof. Shlomo Noy, GIBF's Managing Partner and Chief Medical Officer, said: "CoreBone's Chinese subsidiary started in the technological incubator that our group is managing in Guangzhou according to the principles of the renowned Israeli incubation system. The current subsequent investment by our fund is therefore another great example for our unique success in bringing Israeli companies to China, while protecting their IP and maintaining their own control and management over the Chinese subsidiary. During the incubation period, we had a chance to work closely with CoreBone's team and to make significant progress towards Chinese regulatory approval for its unique products. We are confident that CoreBone will be successful in fulfilling the great unmet medical need it is targeting, partly by our unique capability to perform clinical trials in China."

About Corebone

CoreBone has developed, and is distributing, bioactive, coral-based bone graft material that provides a natural alternative to synthetic or human and animal-derived (bovine, porcine) bone graft material for dental and orthopedic indications. CoreBone is a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), with support from the Israel Innovation Authority.

Contact Information

Ohad Schwartz
+972.52.260.5252 
info@core-bone.com  
https://core-bone.com/

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/corebone-raises-3-7-million-investment-to-commercialize-its-bioactive-bone-graft-material-for-dental-and-orthopedic-treatments--expand-activity-in-china-301391506.html

SOURCE CoreBone

FAQ

What is CoreBone's recent investment round amount?

CoreBone recently raised a total of $3.7 million.

Who invested in CoreBone's latest funding round?

The funding round included $3 million from GIBF and $700,000 from The Trendlines Group and Agriline.

What is the significance of CoreBone's products in China?

CoreBone's coral-based bone grafts are positioned to fill a market gap as China bans the import of human-derived grafts.

How will CoreBone utilize the raised funds?

The funds will be used to extend CoreBone's commercial global presence, particularly in China.

What technology does CoreBone use for its products?

CoreBone uses cultured coral, grown in controlled environments, to produce bioactive bone graft material.